Psychedelic stocks in focus with test trial results coming

The use of psychedelics for depression treatment has made substantial progress in recent years. And industry scientists and entrepreneurs in the industry are expecting FDA approval for its use in medical treatment as early as 2024. Watch for: An important date is coming in the psychedelics industry. A Compass-sponsored trial is testing 3 different doses…

Read more

ETF Spotlight: The first US Psychedelics ETF begins trading

ETF: Defiance Next Gen Altered Experience ETF (NYSE:PSY) Launched last week, $PSY is an ETF that holds 20 companies in the production, distribution, or services related to psychedelics, medical cannabis, and ketamine for health treatments. ETF launch date: May 28, 2021 Top 3 Holdings: Charlottes Web Holdings Inc (TSE:CWEB), Aurora Cannabis (NASDAQ:ACB), Cronos Group (TSE:CRON)…

Read more

Here’s what you need to know about investing in Psychedelic stocks

Biotech companies are pushing magic mushrooms from counterculture to main culture — in what could become the first legalized treatment of depression using psychedelics. Investors are euphoric and psychedelic stocks have surged in 2020: Mind Medicine ($MMED) grew 1,000% Compass Pathways ($CMPS) grew 120% Numinus Wellness ($NUMI) grew 94% Psychedelics are mind-expanding drugs (e.g. LSD, MDMA, and magic…

Read more